Jeff Yass’s Grace Therapeutics GRCE Stock Holding History

Jeff Yass’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$113K	Buy	+49,577	New	+$137K	﹤0.01%	12415
2024 Q3	–	Sell	-37,793	Closed	-$113K	–	13251
2024 Q2	$113K	Buy	37,793 +1,143	+3%	+$3.45K	﹤0.01%	10933
2024 Q1	$126K	Buy	+36,650	New	+$108K	﹤0.01%	11054
2022 Q3	–	Sell	-4,327	Closed	-$22K	–	14287
2022 Q2	$22K	Buy	+4,327	New	+$26.3K	﹤0.01%	12349
2020 Q4	–	Sell	-1,274	Closed	-$12K	–	11840
2020 Q3	$12K	Buy	+1,274	New	+$33.1K	﹤0.01%	10409
2018 Q1	–	Sell	-11,663	Closed	-$528K	–	10334
2017 Q4	$528K	Buy	+11,663	New	+$784K	﹤0.01%	6538
2015 Q1	–	Sell	-49	Closed	-$12K	–	10036
2014 Q4	$12K	Buy	+49	New	+$12.1K	﹤0.01%	9508

Other funds holding GRCE

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Jeff Yass's GRCE Position: Q2 2026 in Review

Jeff Yass opened a new position in Grace Therapeutics (GRCE) in Q2 2026: 49,577 shares worth $113K. The stake represents ﹤0.01% of the portfolio and ranks #12415 among its holdings. This is a return to the name: Jeff Yass previously reported a position in GRCE as recently as Q2 2024.

Jeff Yass first reported a position in GRCE in Q4 2014 and has held it in 7 quarters since. The position peaked at $528K in Q4 2017. 33 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

Jeff Yass held 49,577 shares of Grace Therapeutics worth $113K as of Q2 2026.
Grace Therapeutics was a new Jeff Yass position in Q2 2026.
Grace Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12415 holding.
Jeff Yass first reported a position in Grace Therapeutics in Q4 2014 and has held it in 7 quarters since.
Jeff Yass's Grace Therapeutics position peaked at $528K in Q4 2017.
33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.